Search results
Found 11075 matches for
This month the MRC WIMM hosted the annual Regional Breast Cancer Academic Day, an event that brings together breast cancer teams from across the Thames Valley region. This year’s symposium involved the participation of over 70 attendees, including nurses, clinical trial managers, researchers and doctors.
Skin Immunology Group
MRC TIDU
The aim of the group is to understand, at the molecular and cellular level, the role of human cutaneous immune responses in mechanisms of disease, treatment and vaccination. We have a particular focus on T cells which recognise inflammatory lipids presented by CD1a. As well as contributing to an understanding of disease pathogenesis, we aim to translate our findings to changes in clinical practice.
RAMADAN GROUP
DNA Damage Response
Dong Group | T cell responses against Viruses & Cancer
MRC TIDU
Our group focuses on determining the factors which affect T cells both in the control of viral infection and in the development of cancer.
Koohy Group: Machine Learning and Integrative Approaches in Immunology
Centre for Computational Biology MRC TIDU
We would like to understand the functional and molecular mechanisms of the immune system in various immunologically important conditions such as cancer, infection, autoimmune disease as well as ageing. We have a special interest in computational cancer immunotherapy such as antigen presentation, neo-antigen identification and T cell recognition of neo-antigens as well as interrogating the immune response to personalized vaccines from neo-antigens.
Wilkinson Group: Blood Stem Cell Expansion and Fitness
MRC MHU
Haematopoietic stem cells (HSCs) support blood cell production throughout life and are also used clinically in cell and gene therapies. We are studying the biology of this important stem cell population with the aim of developing new HSC-based therapies.
Sahakyan Group: Integrative Computational Biology and Machine Learning
Centre for Computational Biology
Combining computational biology, computational chemistry, and machine learning techniques with biological big data to unravel the higher genomic code of life.
de Bruijn Group: Developmental Haematopoiesis
MRC MHU
We study the embryonic origins of blood stem cells with the aim to inform the generation of these cells in culture, and ultimate produce clinically relevant blood stem cells for therapeutic purposes.
Psaila Group: The tumour microenvironment in blood cancers
MRC MHU
We focus on four key areas: (1) Dissecting how blood cancers create 'self-reinforcing' niches that promote clonal expansion and protect malignant clones from immunotherapies; (2) Development and application of human bone marrow organoids to study normal and malignant haematopoiesis and validate targets in a relevant tissue microenvironment; (3) Developing novel strategies to selectively target cancer stem cells and pathological megakaryocytes in myelofibrosis, a severe bone marrow malignancy; (4) Understanding our recent discovery that platelets contain a repertoire of DNA fragments sequestered from cell free DNA, and confirming clinical utility for cancer detection and for pre-natal diagnosis.
Simmons Group: Intestinal Immunity in Health and Disease
MRC TIDU
We define how the immune system functions in the intestine to promote health. We uncover the immune pathogenesis of intestinal diseases such as inflammatory bowel disease to develop better ways to treat these disorders.
Chakraverty Group: Haematopoietic Transplantation and Immunotherapy
MRC MHU
Our group is interested in developing novel immunotherapeutic approaches for leukaemia. Clinical approaches currently used include allogeneic haematopoietic stem cell transplantation, chimeric antigen receptor T cell therapy and immune checkpoint inhibitors. While each of these approaches can be successful, they also fail in many patients as a result of tumour adaptations or diminished function of immune cells. Enhanced immunity can also lead to immune-related adverse events due to on- or off-target effects. We are exploring the mechanisms that underpin these failures and using this information to devise new strategies that can be translated into early phase clinical trials.
Childhood Leukaemia Research Group
MRC MHU
Founded in 2015, we are investigating the link between human fetal haematopoiesis and the origin and biology of childhood leukaemia. In particular, we are interested in the pathogenesis of infant leukaemia, which is a refractory disease that invariably originates in utero.
Mead Group: Haematopoietic Stem Cell Biology
MRC MHU
The Haematopoietic Stem Cell Biology (HSCB) Laboratory is focused on understanding how the normal haematopoietic stem/progenitor hierarchy is disrupted during the development of myeloid malignancies. Our overarching aim is to improve the management of myeloproliferative neoplasms and related conditions through better monitoring and therapeutic targeting of malignant stem cell populations.